The retatrutide dosage schedule after high-dose tirzepatide provides protocol guidance for this increasingly discussed transition
That is normal
Higher-risk situations may include: Older age Existing sarcopenia or frailty Recent falls Difficulty rising from a chair Low baseline physical activity Very low protein or calorie intake Rapid or excessive appetite suppression Chronic kidney, liver, pulmonary, or cardiovascular disease Cancer or another catabolic illness Recent hospitalization Significant gastrointestinal adverse effects Very rapid weight loss Inability to participate in resistance exercise These factors do not automatically make GLP-1 therapy inappropriate
Rob Berberian works with every patient to determine whether they are dealing with temporary shedding, underlying pattern hair loss, or a combination of both, an important distinction that shapes the entire treatment plan
GLP-1 RA-MWL leads to AT depletion, with associated skin laxity, volume loss, and accelerated aging, particularly in periorbital and midfacial regions
For general reconstitution guidance, see how to reconstitute peptides
